Literature DB >> 2310159

Immunoradiometric assay for intact human parathyroid hormone: characteristics, clinical application and comparison with a radio-immunoassay.

M Frölich1, S T Walma, C Paulson, S E Papapoulos.   

Abstract

Circulating immunoreactive intact human parathyroid hormone (PTH) was measured by a direct immunoradiometric assay (IRMA) and the results compared with a radio-immunoassay (RIA) which required extraction and concentration prior to assay. The sensitivity of the IRMA was better than that of the RIA (0.6 vs 2.0 pmol/L). In control subjects the hPTH concentrations ranged between 0.6 and 6.7 pmol/L and in patients with hypercalcaemia due to malignant diseases, sarcoidosis and hypoparathyroidism none could be detected. In patients with primary hyperparathyroidism the concentrations ranged from 5.2 to 27.0 pmol/L. In patients with renal osteodystrophy serum human PTH concentrations ranged from 7.6 to 285 and in those with chronic renal failure but without evidence of renal osteodystrophy from 0.5 to 5.2 pmol/L. The major advantages of the IRMA are its much simpler performance and its higher sensitivity which makes studies of the physiology of PTH secretion in humans possible.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2310159     DOI: 10.1177/000456329002700114

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  3 in total

1.  Adsorption of oxacalcitriol by polysulphone haemodialyser in patients with secondary hyperparathyroidism.

Authors:  Shuichi Tsuruoka; Hisashi Yamamoto; Takashi Ioka; Hitoshi Ando; Tetsuo Saito; Akio Fujimura
Journal:  Br J Clin Pharmacol       Date:  2004-11       Impact factor: 4.335

2.  Uninterrupted oral bisphosphonate (pamidronate) therapy of patients with osteoporosis is not associated with chronic stimulation of parathyroid hormone secretion.

Authors:  J O Landman; S E Papapoulos
Journal:  Osteoporos Int       Date:  1995-03       Impact factor: 4.507

3.  Chronotherapy of high-dose active vitamin D3 in haemodialysis patients with secondary hyperparathyroidsm: a repeated dosing study.

Authors:  Shuichi Tsuruoka; Michi Wakaumi; Koichi Sugimoto; Tetsuo Saito; Akio Fujimura
Journal:  Br J Clin Pharmacol       Date:  2003-06       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.